EUGENICS #2: Developers of Oxford-AstraZeneca Vaccine Tied to UK Eugenics Movement

Quote of the week
“If people can be educated to see the lowly side of their own natures, it may be hoped that they will also learn to understand and to love their fellow men better. A little less hypocrisy and a little more tolerance towards oneself can only have good results in respect for our neighbor; for we are all too prone to transfer to our fellows the injustice and violence we inflict upon our own natures."
― Carl Jung
Past Quotes of the WeekShow more

Home Activism Global Research Developers of Oxford-AstraZeneca Vaccine Tied to UK Eugenics Movement
Developers of Oxford-AstraZeneca Vaccine Tied to UK Eugenics Movement
Justin Case March 2, 2021Global Research, Health Watch, News Health
The developers of the Oxford-AstraZeneca vaccine have previously undisclosed ties to the re-named British Eugenics Society as well as other Eugenics-linked institutions like the Wellcome Trust.

By JEREMY LOFFREDO AND WHITNEY WEBB published DECEMBER 26, 2020

On April 30, AstraZeneca and the University of Oxford announced a “landmark agreement” for the development of a COVID-19 vaccine. The agreement involves AstraZeneca overseeing aspects of the development as well as manufacturing and distribution while the Oxford side, via the Jenner Institute and Oxford Vaccine Group, researched and developed the vaccine. Less than a month after this agreement was reached, the Oxford-AstraZeneca partnership was awarded a contract from the US government as part of Operation Warp Speed, the public-private COVID-19 vaccination effort dominated by the US military and US intelligence.

Though the partnership was announced in April, Oxford’s Jenner Institute had already begun developing the COVID-19 vaccine months before, in mid-January. According to a recent BBC report, it was in January that the Jenner Institute first became aware of how serious the pandemic would soon become, when Andrew Pollard, who works for the Jenner Institute and heads the Oxford Vaccine Group, “shared a taxi with a modeler who worked for the UK’s Scientific Advisory Group for Emergencies.” During the taxi ride, “the scientist told him data suggested there was going to be a pandemic not unlike the 1918 flu.” Because of this sole encounter, we are told, the Jenner Institute began to pour millions into the early development of a vaccine for COVID-19, well before the scope of the crisis was clear.

For much of 2020, the Oxford-AstraZeneca vaccine was treated as an early frontrunner, though its lead would later be marred by scandals related to its clinical trials, including the death of participants, sudden trial pauses, the use of a problematic “placebo” with its own host of side effects, and the “unintentional” misdosing of some participants that skewed its self-reported efficacy rate.

The significant issues that emerged during trials have provoked little concern from the vaccine’s two lead developers, despite critical attention from even mainstream media directed at its complications. The lead developer of the Oxford-AstraZeneca vaccine, Adrian Hill, told NBC on December 9 that the experimental vaccine should be approved and distributed to the public before the conclusion of the safety trials, saying “to wait for the end of the trial would be the middle of next year. That’s too late, this vaccine is effective, available at large scale and easily deployed.”

Sarah Gilbert, the other lead researcher on the vaccine, seemed to believe that premature safety approval was likely, telling the BBC on December 13 that the chances of rolling out the vaccine by the end of the year are “pretty high.” Now, the UK is expected to approve the Oxford-AstraZeneca vaccine shortly after Christmas, with India also set to approve the vaccine next week.